CClinicalTrials.gg
CompletedNCT03750097Updated Apr 12, 2019

Validation of a Smartwatch in Persons With Multiple Sclerosis

An interventional study of Comfortable walking velocity (CWV) and Slow walking velocity (SWV: CWV - 20%) in Multiple Sclerosis, sponsored by University of Erlangen-Nürnberg. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-12.

Sponsored by University of Erlangen-Nürnberg · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is designed to validate the accuracy of steps detected by a commercially available smartwatch in persons with multiple sclerosis. Specifically, the investigators examine whether a smartwatch can detect steps accurately during slow, comfortable and fast overground walking. The total steps counted by the smartwatch will be compared to those counted by an accelerometer commonly used in clinical studies and the actually walked steps.

Read the detailed description

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. It is one of the most common neurological diseases in young adulthood. The main symptoms of MS are gait and mobility impairments, which also determine the severity of the disease. Currently, subjective clinical functional tests are commonly used to evaluate therapy outcomes. Due to advancing mechanization, body-worn accelerometers have been established as a potential instrument for the objective detection of mobility in clinical research. The accuracy of these devices for determining the mobility is therefore essential. However, current studies, especially in people with altered gait, show large deviations in step detection accuracy.

In the present study we want to investigate: i) whether a commercially available smartwatch (Polar M600) counts steps in persons with multiple sclerosis (pwMS) accurately and ii) whether it counts steps as accurately as an accelerometer commonly used in clinical research (ActiGraph wGT3X-BT). In addition, the accuracy of the step detection by the algorithms of the manufacturer of the two devices (Polar M600 and ActiGraph wGT3X-BT) will be compared with an own-developed algorithm.

For this purpose, 63 pwMS with low to severe functional restriction (EDSS: 0 - 6.5) will participate in this validation study. The validation protocol consists of three walking tests with different walking velocities. During these three conditions the participants will wear the Polar M600 on the wrist and the ActiGraph wGT3X-BT with a belt over the hip. In the first walking test, the subjects will complete 250 steps with comfortable walking velocity (CWV). After a sufficient break, the participants will be randomly assigned to either a fast walking velocity condition (FWV: CWV + 20%) followed by a sufficient period of rest and a slow walking velocity condition (SWV: CWV - 20%) or vice versa. Each of the walking tests with modified walking velocity also consists of 250 steps. To analyze the accuracy of step detection, the measured steps of the devices will be compared with the actually walked 250 steps.

02

Conditions studied

  • Multiple Sclerosis

Keywords

  • Multiple Sclerosis
  • Motion sensors
  • Smartwatch
  • Steps
  • Walking
  • Validation
03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's enrollment of 58 is above the median of 50 across 2,342 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

University of Erlangen-Nürnberg is the lead sponsor of 21 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Multiple Sclerosis with Expanded Disability Status Scale between 0 - 6.5
  • Ability to walk 250 steps with or without an assistive device

Exclusion criteria

Exclusion Criteria:

  • Clinically relevant cardiovascular or orthopaedic disease
  • Severe polyneuropathy
  • Cognitive impairment
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Walking protocol

    Walking for 250 steps with comfortable walking velocity (CWV), slow walking velocity (SWV: CWV - 20%) and fast walking velocity (FWV: CWV + 20%) with sufficient rest between conditions.

    Behavioral: Comfortable walking velocity (CWV) · Behavioral: Slow walking velocity (SWV: CWV - 20%) · Behavioral: Fast walking velocity (FWV: CWV + 20%)

Interventions

  • BehavioralComfortable walking velocity (CWV)

    Walking for 250 Steps with self-selected comfortable walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT)

  • BehavioralSlow walking velocity (SWV: CWV - 20%)

    Walking for 250 Steps with slow walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Slow walking consists of walking with 20% slower than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.

  • BehavioralFast walking velocity (FWV: CWV + 20%)

    Walking for 250 Steps with fast walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Fast walking consists of walking with 20% faster than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.

06

What researchers measure

Primary outcomes

  1. Step detection during comfortable walking

    Step detection accuracy of the two devices (Polar M600 and ActiGraph wGT3X-BT) for both the standard algorithm and the self-developed algorithm during comfortable walking for 250 steps.

    Time frame: Following the comfortable walking velocity protocol, an average of 2 minutes

Secondary outcomes

  1. Step detection during slow walking

    Step detection accuracy of the two devices (Polar M600 and ActiGraph wGT3X-BT) for both the standard algorithm and the self-developed algorithm during slow walking for 250 steps.

    Time frame: Following the slow walking velocity protocol, an average of 2 minutes

  2. Step detection during fast walking

    Step detection accuracy of the two devices (Polar M600 and ActiGraph wGT3X-BT) for both the standard algorithm and the self-developed algorithm during fast walking for 250 steps.

    Time frame: Following the fast walking velocity protocol, an average of 2 minutes

07

Study locations

1 site
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Department of Sport Science and Sport, Gebbertstr. 123b
    Erlangen, 91058, Germany
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03750097
Lead sponsor
University of Erlangen-Nürnberg
Collaborators
Neurological Rehabilitation Center Quellenhof, ZTM Bad Kissingen
Responsible party
Prof. Dr. Klaus Pfeifer (Prof. Dr., University of Erlangen-Nürnberg) — Principal investigator
First posted
Nov 21, 2018
Start date
May 1, 2018
Primary completion
Dec 15, 2018
Completion
Jan 31, 2019
Last update
Apr 12, 2019

Study contacts

Klaus Pfeifer, Prof. Dr.
principal investigator · Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Department of Sport Science and Sport
Peter Flachenecker, Prof. Dr. med.
principal investigator · Neurological Rehabilitation Center Quellenhof

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion